

Checklist for Legembi (lecanemab) Referral

Patient	nt Name:	DOB:		Date:	
Referri	rring Physician:		NPI:		
Office	e Contact/Title/Email:				
Office A	e Address:				
Office	e Phone:	Office Fax:			
Best co	contact number for physician in case of reaction	n:			
Please	e return completed checklist and checklist items t	to initiate referro	al. Use this form	as fax cover sheet.	
	Patient demographic information				
	Insurance information and copy of insurance of	card/s (front and	l back). *Include	primary and secondary insurance	
	Supporting clinical notes and office visits. Two	notes preferred	d.		
	 Note should include any therapies trie 	ed/failed, and m	ust include discu	ssion about Leqembi	
	 Medication list and allergies 				
	Cognitive assessment and functional a Supporting lab reports / imaging for Logambi to		score and interp	pretation	
u		reatment			
	MRI within 1 year of treatment start				
	 Confirmation of amyloid beta patholo 	gy (LP or PET Sca	an)		
	 Recommended: ApoE testing to deter 	mine ARIA risk			
	Durable Power of Attorney for Health Care (Di	PAHC), if applica	ble		
	Leqembi Prescribing Order (see attached)				
	Leqembi Indication Checklist (see attached)				

Fax all information to our Infusion Coordinator: 508-698-8671

Call with any questions: 781-551-5812 ext. 112



Prescribing Order: Legembi (lecanemab)

Patient Name: DOB: M/F: Diagnosis (include ICD-10 code/s): NKDA	-							
Patient Name:	Ordering Provider Name		NPI					
Patient Name:								
Patient Name:	✓	•		. Notify physician.				
Patient Name:	✓ Hold infusion and notify provider if patient experiencing any of the following signs of ARIA:							
Patient Name: DOB:								
Patient Name:			infusion if no MRI Brain prior to the 5 th 7 th and 14 th infusion, then annually					
Patient Name: DOB: M/F: Diagnosis (include ICD-10 code/s): NKDA Allergies: Patient Weight: Premedication: Acetaminophen 1000mg PO Diphenhydramine 25mg IV Solu-medrol 125mg IV in 50ml over 15min Diphenhydramine 25mg PO Other:	Administra	ation:						
Patient Name: DOB: M/F: Diagnosis (include ICD-10 code/s): NKDA Allergies: Patient Weight: Premedication: Acetaminophen 1000mg PO Diphenhydramine 25mg IV Solu-medrol 125mg IV in 50ml over 15min Diphenhydramine 25mg PO Other:	□ Ot	tner:	-					
Patient Name:		No. and						
Patient Name:			um Chloride infused over 1 hour every 2 weeks					
Patient Name: DOB: M/F: Diagnosis (include ICD-10 code/s): NKDA Allergies: Patient Weight: Premedication: Acetaminophen 1000mg PO Diphenhydramine 25mg IV Loratadine 10mg or Cetirizine 10mg PO Solu-medrol 125mg IV in 50ml over 15min Diphenhydramine 25mg PO Other:	LEOEMBLI	Medication Order:						
Patient Name: DOB: M/F: Diagnosis (include ICD-10 code/s): NKDA Allergies: Patient Weight: Premedication: Acetaminophen 1000mg PO Diphenhydramine 25mg IV Loratadine 10mg or Cetirizine 10mg PO Solu-medrol 125mg IV in 50ml over 15min Diphenhydramine 25mg PO Other:	U							
Patient Name: DOB: M/F: Diagnosis (include ICD-10 code/s): NKDA Allergies: Patient Weight: Premedication: Diphenhydramine 25mg IV Diphenhydramine 1000mg PO Diphenhydramine 25mg IV Solu-medrol 125mg IV in 50ml over 15min	_							
Patient Name:	■ Dipliei	mydramme 25mg PO	Guiler.					
Patient Name: DOB: M/F: Diagnosis (include ICD-10 code/s): NKDA Allergies: Patient Weight: Premedication: Acetaminophen 1000mg PO Diphenhydramine 25mg IV		•	_					
Patient Name: DOB: M/F: Diagnosis (include ICD-10 code/s): NKDA Allergies: Patient Weight: Premedication:		•		ml over 15min				
Patient Name: DOB: M/F: Diagnosis (include ICD-10 code/s): NKDA Allergies: Patient Weight:			☐ Dinhenhydramine 25mg IV					
Patient Name: DOB: M/F: Diagnosis (include ICD-10 code/s):	Duomodias	ation.						
Patient Name: DOB: M/F: Diagnosis (include ICD-10 code/s):	Patient We	eight:						
Date of last infusion: Patient Name: DOB: M/F:	□ NKDA	Allergies:						
Date of last infusion: Patient Name: DOB: M/F:	Diagilosis	(iliciade ICD-10 code/s)		-				
Date of last infusion:	Diagnosis	(include ICD-10 code/s):						
	Patient Na	ame:	DOB:	M/F:				
			Date of last infusion	on:				
			Data affects for					



LEQEMBI Indication Checklist

	INFORMATION REQUIRED FOR TREATMENT INITIATION			
1)	Patient ICD-10 (select all that apply) Clinical Diagnosis (select one)			
	G30.0 Alzheimer's disease with early Mild cognitive impairment due to AD			
	onset			
	G30.1 Alzheimer's disease with late onset			
	G30.9 Alzheimer's disease, unspecified			
2)	G31.84 Mild cognitive impairment Cognitive Screening: within 6 months Date:			
۷)	Cognitive Screening: within 6 months Date.			
	Name of Test Used: Score:			
	Interpretation:			
	Functional Screening: within 6 months Date:			
	Name of Test Used: Score:			
	Interpretation:			
3)	Confirmation of Amyloid-Beta Pathology: MUST provide supporting documentation			
	☐ Amyloid PET Scan Date: Result:			
	☐ CSF Amyloid Confirmation Date: Result:			
Notes:				
4)	Monitoring for Amyloid Related Imaging Abnormalities (ARIA)			
.,	***LEQEMBI requires brain MRI within 1 year of treatment start date***			
	☐ Initial MRI Brain Date:			
	Result:			
	Evidence of ARIA-E Negative Positive			
	Evidence of ARIA-H Negative Positive			
5)	Schedule for MRI Monitoring: the following is required by Infusion Center of New England			
,	Obtain MRI prior to the 5 th , 7 th , and 14 th infusion, then annually			
Notes:				
6)	Is the patient on anticoagulation?			
7)	Is the patient on antiplatelets?			
8)	Has ApoE testing been performed? ☐ Yes ☐ No Result:			
9)	CMS REGISTRATION NUMBER			
•	(REQUIRED) Date:			